Заключение

Клеточные и молекулярные механизмы патогенеза БП активно изучаются в последние два десятилетия. Особое значение имеют результаты клинических исследований, проведенных с помощью неинвазивных нейровизуализационных методов и патоанатомических исследований, выполненных на аутопсийном материале, полученном в терминальной фазе клинической стадии (Угрюмов, 2010; Betarbet et al., 2000b; Bezard et al., 2001; Palfi et al., 2002; Sandmann-Keil, Braak, 2005; Ugrumov, 2008).

Литература

ДегтяреваEA., Пронина Т.С., УгрюмовМ.В. Состояние тубероинфундибулярной дофаминергической системы при моделировании паркинсонизма у мышей // Нейрохимия.

Дильмухаметова Л.К., Пронина Т.С., Зиязетдинова ГЗ. и др. Роль норадреналина в развитии дофа- мин-зависимой гиперпролактинемии // Нейрохимия. 2009. Т 26. № 4. С. 318-327.

Козина E.A., Хаиндрава В.Г., Кудрин В.С. и др. Экспериментальное моделирование функциональной недостаточности нигростриатной дофаминергической системы у мышей // Рос. физиол. журнал. 2010. Т 96. № 3. С. 270-282.

Калачева AA., Козина E.A., Волина E.B., Угрюмов М.В. Дегенерация нигростриатных дофаминерги- ческих нейронов на экспериментальной модели ранней клинической стадии болезни Паркинсона // Нейрохимия. 2014. Т 31. № 3. С. 225-235.

Кршжановский Г.Н., Атаджанов M.A., Магаева С.В. и др. Изменения ЭЭГ и явления паркинсонизма при интракаудатном введении антител к дофамину // Бюлл. экспер. биол. и мед. 1989. № 1. С. 13-16.

Крыжановский Г.Н., Евсеев В.А., Магаева С.В. и др. Антитела к дофамину в патогенезе паркинсонизма // Бюлл. экспер. биол. и мед. 1991. № 1. С. 16-19.

Крыжановский Г.Н., Атаджанов М.А., Воронина T.A., Неробкова Л.Н. Особенности паркинсоничес- кого синдрома, вызванного в эксперименте дефицитом нигростриатного дофамина и стимуляцией холинергических нейонов хвостатых ядер // Журн. невр. и псих. им. С.А. Корсакова. 1993. № 6. С. 3-6.

Крыжановский Г.Н., Магаева С.В., Макаров С.В. Нейроиммунопатология. М.: НИИ общей патологии и патофизиологии РАМН, 1997. 284 с.

Крыжановский Г.Н., Карабань И.Н., Магаева С.В. и др. Болезнь Паркинсона: Этиология, патогенез, клиника, лечение, профилактика. М.: Медицина, 2002. 336 с.

Кучеряну В.Г., Крыжановский Г.Н. Влияние глутамата и антагонистов ^метил^-аспартатрецепто- ров на экспериментальный паркинсонический синдром у крыс // Бюлл. экспер. биол. и мед. 2000. Т 130. С. 20-23.

Нигматуллина Р.Р., Кириллова В.В., Лбдульяпов B.A. и др. Экспрессия 5-НТ2в-рецепторов в миокарде правого предсердия и концентрация серотонина в крови у больных с хронической сердечной недостаточностью // Вестник межрегионального клинико-диагностического центра.

РодионовИ.М. Иммунологическая и химическая десимпатизация. М.: Наука, 1988. 149 с.

Угрюмов М.В. Экспрессия ферментов синтеза дофамина в недофаминергических нейронах: функциональное значение и регуляция // Успехи физиол. наук. 2007. Т. 38, № 4. С. 3-20.

Угрюмов М.В. Новые представления о патогенезе, диагностике и лечении нейродегенеративных заболевании // Вестник РАМН. 2010. № 8. С. 6-19.

Украинцева Ю.С., Щеголевский Н.В., Коршунов В.Л. и др. Моделирование досимптомной стадии паркинсонизма у мышей - анализ выделения дофамина в стриатуме // Нейрохимия. 2010. Т 27. № 2. С. 164-169.

Хаиндрава В.Г., Козина EA., Кучеряну В.Г. и др. Моделирование доклинической и ранней клинической стадий болезни Паркинсона // Журн. невр. и псих. им. С.С. Корсакова. 2010а. № 7. С. 41-47.

Хаиндрава В.Г., Кудрин В.С., Кучеряну В.Г и др. Экспериментальное моделирование клинической и преклинической стадий болезни Паркинсона // Бюл. экспер. биол. и мед. 2010б. Т 150. № 11. С. 494-498.

Хакимова Г.Р., Козина EA., Сапронова Л.Я., Угрюмое М.В. Обратный захват дофамина в черной субстанции и стриатуме на досиптомной и ранней симптомной стадиях паркинсонизма у мышей // Докл. РАН. 2010. Т 435. № 2. С. 272-274.

Хакимова Г.Р., Козина Е.А., Сапронова А.Я., УгрюмоеМ.В. Выделение дофамина в черной субстанции и стриатуме на досиптомной и ранней симптомной стадиях паркинсонизма у мышей // Нейрохимия. 2011. Т 28. № 1. С. 42-48.

Хакимова Г.Р., КозинаЕ.А., Бунеееа О.А. и др. М.В. Активность моноаминоксидазы в нигростриатной системе на досимптомной и ранней симптомной стадиях паркинсонизма у мышей //Бюл. экспер. биол. и мед. 2014 (в печати).

Abercrombie E.D., Keefe KA., Strieker E.M. et al. Environmental stress increases extracellular dopamine in striatum of 6-hydroxydopamine-treated rats: in vivo microdialysis studies // Brain Res. 1990. Vol. 527. № 2. P. 350-353.

Abou-SIeiman P.M., Healy D.G., Wood N.W. Causes of Parkinson’s disease: Genetics of DJ-1 // Cell Tissue Res.

Agid Y. Parkinson’s disease: pathophysiology // Lancet. 1991. Vol. 337. P. 1321-1324.

Ahlskog J.E. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease // Mov. Disord. 2004. Vol. 20. P. 271-282.

Akazawa Y.O., Saito Y., Hamakubo T. et al. Elevation of oxidized DJ-1 in the brain and erythrocytes of Parkinson disease model animals // Neurosci. Lett. 2010. Vol. 483. P. 45-205.

AlbrechtM. LRRK2 mutations and Parkinsonism // Lancet. 2005. Vol. 365. № 9466. P. 1230.

Algeri S., Ambrosio S., Garofalo P. et al. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat // Eur. J. Pharmacol. 1987. Vol. 141. P. 309-312.

Al-Jarrah M., Pothakos K., Novikova L. et al. Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration // Neurosci. 2007. Vol. 149. P. 28-37.

Alvarez-Fiseher D., Guerreiro S , Hunot S. et al. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid // J. Neurochem. 2008. Vol. 107. N 3. P. 701-711.

Ambrosio S., Blesa R., Mintenig G.M. et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines in heart, adrenal gland, retina and caudate nucleus of the cat // Toxicol. Lett. 1988. Vol. 44. P. 1-6.

Amino T., Uehihara T., Tsunekawa H. et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction // Neurosci. Res. 2008. Vol. 60. P. 314-318.

Andres-Mateos E., Mejias R., Sasaki M. et al. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) // J. Neurosci. 2009. Vol. 29. № 50. P. 15846-15850.

Ara J., Przedborski S., Naini A.B. et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) // J.

Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri- dine (MPTP)-treated C57 black mouse model for parkinsonism // Brain Res. 1990. Vol. 515. № 1. P. 57- 63.

Arima K., Hirai S., Sunohara N. et al. Cellular co-localization of phosphorylated tau- and NACP/alpha- synuclein-epitopes in lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies // Brain Res. 1999. Vol. 843. № 1-2. P. 53-61.

Baba M., Nakajo S., Tu P.H. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies // Am. J. Pathol. 1998. Vol. 152. № 4. P. 879-884.

Baba Y., Kuroiwaa A., Uittie R.J. et al. Alterations of T-lymphocyte populations in Parkinson disease // Parkinsonism and Related Disorders. 2005. Vol. 11. P. 493-498.

Bandopadhyay R., Kingsbury A.E., Cookson M.R. et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease // Brain. 2004. Vol. 127. P. 420-430.

Bankiewiez K.S., Oldfi eld E.H., Chiueh C.C. et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) // Life Sci. 1986. Vol. 39. № 1. P. 7-16.

Barbie F., Perego F., Canesi M. et al. Early abnormalities of vascular and cardiac autonomic control in Parkinson’s disease without orthostatic hypotension // Hypertension. 2007. Vol. 49. P. 120-126.

Behrouz В., Drolet R.E., Sayed Z.A. et al. Unique responses to mitochondrial complex I inhibition in tuber- oinfundibular dopamine neurons may impart resistance to toxic insult // Neurosci. 2007. Vol. 47. № 3. P. 592-598.

Benskey M., Behrouz В., Sunryd J. et al. Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression // Neurotoxicology. 2012. Vol. 33. № 3. P. 321-331.

Benskey M., Lee K.Y., Parikh K. et al. Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein // Neurotoxicology. 2013. Vol. 37. P. 144-153.

Bergstrom В.Р., Garris P.A. «Passive stabilization» of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson’s disease: a voltammetric study in the 6-OHDA-lesioned rat // J. Neurochem. 2003. Vol. 87. T 5. P 1224-1236.

Bernheimer H., Birkmayer W., Hornykiewicz O. et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations // J. Neurol. Sci. 1973. Vol. 20. № 4. P 415-455.

Betarbet R., Porter R.H., Greenamyre J.T. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation // J. Neurochem. 2000a. Vol. 74. T 3. R 1166-1174.

Betarbet R., Sherer Т.В., MacKenzie G. et al. Garcia-Osuna MChronic systemic pesticide exposure reproduces features of Parkinson’s disease // Nat Neurosci. 2000b. Vol. 3. N 12. P .1301-1306.

Bezard E., Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach // Prog. Neurobiol. 1998. Vol. 55. № 2. P. 93-116.

Bezard E., Dovero S., Bioulac В., Gross C.E. Kinetics of nigral degeneration in a chronic model of MPTP- treated mice // Neurosci. Lett. 1997. Vol. 234. № 1. P. 47-50.

Bezard E., Dovero S., Prunier C. et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease // J. Neurosci. 2001. Vol. 21. № 17. P. 6853-6861.

Bezard E., Yue Z., Kirik D., Spillantini M.G. Animal models of Parkinson’s disease: limits and relevance toneuroprotection studies //Mov. Disord. 2013. Vol. 28. № 1. P. 61-70.

Biskup S., Moore D.J., Celsi F. et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain // Ann. Neurol. 2006. Vol. 60. T. 5. P. 557-569.

Blanchard V., Raisman-Vozari R., Savasta M. et al. Cellular quantification of tyrosine hydroxylase in the rat brain by immunoautoradiography // J. Neurochem. 1993. Vol. 2. P. 617-626.

BlanchetP.J., Calon F., Morissette M. et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms // Parkinsonism Relat. Disord. 2004. Vol. 10. T. 5. P. 297-304.

Block M.L, Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with acommon mechanism // Prog. Neurobiol. 2005. Vol. 76. № 2. P. 77-98.

Bogdanov M., Matson W.R., Wang L. et al. Metabolomic profiling to develop blood biomarkers for Parkinson’s disease // Brain. 2008. Vol. 131. P. 389-396.

Bonuccelli U., Fariello R.G. Evidence for an epileptogenic action of 1-methyl-4-phenyl-1,2,3,6,-tetrahydro- pyridine // Neuropharmacology. 1989. Vol. 28. P. 1419-1422.

Bosler O., Calas A. Radioautographic investigation of monoaminergic neurons: an evaluation // Brain Res. Bull. 1982. Vol. 9. P 151-169.

Bouhaddi M., Vuillier F., Fortrat J.O. et al. Impaired cardiovascular autonomic control in newly and long- term-treated patients with Parkinson’s disease: involvement of L-dopa therapy // Autonomic Neuroscience: Basic and Clinical. 2004. Vol. 116. P. 30-38.

BraakH., BraakE. Pathoanatomy of Parkinson’s disease // J. Neurol. 2000. Vol. 247. Suppl. 2. P. 3-10.

Braak H., Del Tredici K., Bratzke H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages) // J. Neurol. 2002. Vol. 249. Suppl. 3ТП/1-5.

Braak H., Del Tredici K., Rub U. et al. Staging of brain pathology related to sporadic Parkinson’s disease // Neurobiol Aging. 2003. Vol. 24. № 2. P 197-211.

Brinkley B.R., Barham S.S., Barranco S.C. et al. Rotenone inhibition of spindle microtubule assembly in mammalian cells // Exp. Cell. Res. 1974. Vol. 30. T. 85. № 1. P 41-46.

Bronstein D.M., Perez-Otano I., Sun V et al. GLIA-Dependent neurotoxicity and neuroprotection in mesencephalic cultures // Brain Res. 1995. Vol. 704. № 1. P. 112-116.

Brooks A.I., Chadwick CA., Gelbard H.A. et al. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss // Brain Res. 1999. Vol. 823. № 1-2. R 1-10.

Bucerius J., Joe A.Y., Schmaljohann J. et al. Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo // Clin. Res. Cardiol. 2006. Vol. 2. P. 105-109.

Burns R.S., Chiueh C.C., Markey S.P. et al. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine // Proc. Natl. Acad. Sci. USA. 1983. Vol. 80. P. 4546-4550.

Butcher S.P., Fairbrother I.S., Kelly J.S. et al. // J. Neurochem. 1990. Vol. 55. P. 981-988.

Cadete L.M., Katz L., Jackson L.V., Fahn S. Vitamin E attenuate toxic effect of intrastriatal injection of 6-hydroxydopamine (6 -OHDA) in cats. Behavioral and biochemical evidence // J. Neurochem. 1989. Vol. 476. P. 10-15.

Callier S., Morissette M., Grandbois M. et al. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice // Synapse. 2001. Vol. 41. № 2. P. 131-138.

Cano-JaimezM., Perez-Sanchez F., Milan M. et al. Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by a-synuclein // Neurobiol. Disease. 2010. Vol. 38. P. 92-103.

Cartelli D., Casagrande F., Busceti C.L. et al. Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective // Sci. Rep. 2013. Vol. 3. P. 1837.

Castaneda E., Whishaw I.Q., Robinson T.E. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size // J. Neurosci. 1990. Vol. 10. № 6. P. 1847-1854.

Chandra S., Fornai F., Kwon H.B. et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions // Proc. Natl. Acad. Sci. USA. 2004. Vol. 101. № 41. P. 14966-14971.

Chang F.W., Wang S.D., Lu K.T., Lee E.H. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and thelocus coeruleus in BALB/c mice // Brain Res. Bull. 1993. Vol. 31. P. 253-266.

Chartier-Harlin M.C., Kachergus J., Roumier C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease // Lancet. 2004. Vol. 64. № 9440. P 1167-1169.

ChesseletM.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson’s disease? // Exp. Neurol. 2008. Vol. 209. P. 22-27.

Chesselet M.F., Richter F., Zhu C. et al. A progressive mouse model of Parkinson’s disease: the Thy1-aSyn («Line 61») mice // Neurotherapeutics. 2012. Vol. 9. № 2. P. 297-314.

Chien K.R., Zhu H., Knowlton K.U. et al. Transcriptional regulation during cardiac growth and development // Annu. Rev. Physiol. 1993. Vol. 55. P. 77-95.

Cicchetti F., Lapointe N., Roberge-TremblayA. et al. Systemic exposure to paraquat and maneb models early Parkinson’s disease in young adult rats / /Neurobiol. Dis. 2005. Vol. 20. № 2. P. 360-371.

Clark D.G., McElligott T.F., Hurst E.W. The toxicity of paraquat // Br. J. Ind. Med. 1966. Vol. 23. №2. P. 126-132.

Cohen G., Werner P. Free radicals, oxidative stress, and neurodegeneration // Neurodegenerative Diseases. Ed. D.B. Calne. 1994. P. 139-161.

Cookson M.R. The biochemistry of Parkinson’s disease // Annu. Rev. Biochem. 2005. Vol. 74. P. 29-52.

Cui M., Aras R., Christian W.V et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. № 19. P. 8043-8048.

Cutillas B., Espejo M., Gil J. et al. Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration // Neuroreport. 1999. Vol. 20. T. 10. № 12. P. 2605-8.

Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models // Neuron. 2003a. Vol. 11. T. 39. №6. P. 889-909.

Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models // Neuron. 2003b. Vol. 39. № 6. P. 889-909.

Dauer W., Kholodilov N., Vila M. et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP// Proc. Natl. Acad. Sci. USA. 2002. Vol. 29. T 99. № 22. P. 14524-14529.

Dawson T.M., Dawson V.L. Parkin plays a role in sporadic Parkinson’s disease // Neurodeg. Dis. 2014. Vol. 3. № 2-3. P. 69-71.

Dawson TM., KoH.S., Dawson VL Genetic animal models of Parkinson’s disease // Neuron. 2010. Vol. 66. № 5. P 646-661.

Decamp E., Tinker J.P., Schneider J.S. Attentional cueing reverses deficits in spatial working memory task performance in chronic low dose MPTP-treated monkeys // Behav. Brain Res. 2004. Vol. 152. № 2. P 259-262.

Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms // Free Radical Biology and Medicine. 2013. Vol. 62. P. 132-144.

Drolet R.E., Behrouz B., Lookingland KJ. et al. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration // Neurotoxicology. 2004. Vol. 25. T 5. P 761-769.

Du Y, Ma Z., Lin S. et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP- model of Parkinson’s disease // Proc. Natl. Acad. Sci. US A. 2001. Vol. 98. № 25. P. 14669-14674.

Dunnett S.B., BJorkIund A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease // Nature. 1999. Vol. 399. № 6738 (Suppl). Р A32-A39.

Dusonchet J., Kochubey O., Stafa K. et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2 // J. Neurosci. 2011. Vol. 31. P. 907-912.

EbertA.D., Hann HJ., BohnM.C. Progressive Degeneration of Dopamine Neurons in 6-Hydroxydopamine Rat Model of Parkinson’s Disease Does Not Involve Activation of Caspase-9 and Caspase-3 // J. Neurosci. Res. 2007. Vol. 86. № 2. P 317-325.

Edwards АЖ, Jones C.T. Adrenal cortical and medullary responses to acetylcholine and vasoactive intestinal peptide in conscious calves // J. Physiol. 1993. Vol. 468. P 515-527.

Faull R.L., Laverty R. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra // Exp. Neurol. 1969. Vol. 23. № 3. P 332-340.

Feany M.B, Bender W.W. A Drosophila model of Parkinson’s disease // Nature. 2000. Vol. 404. P. 394-398.

Fernagut P.0, Hutson C.B., Fleming S.M. et al Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression // Synapse. 2007. Vol. 1. № 12. P 991-1001.

Ferrante RJ., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra // Brain Res. 1997. Vol. 753. № 1. P 157-162.

Ferrari C.C., Pott Godoy M.C. Progressive neurodegeneration and motor isabilities induced by chronic ex- pressionof IL-1beta in the substantia nigra // Neurobiol. Dis. 2006. Vol. 24. № 1. P. 183-193.

Ferrer I., Martinez А., Blanco R. et al. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease // J. Neural. Transmission. 2011. Vol. 118. P 821-839.

Finn M., Mayorga AJ., Bittman K., Salamone D. Animal models of parkinsonian symptims: involvement of pallidal and nig ral GABA in generation of takrine-induced jam tremor in rats // Abstr. Soc. Neurosci. 1996. Vol. 22. № 3. P 2129.

Fleming S.M. Cardiovascular autonomic dysfunction in animal models of Parkinson’s disease // J. Parkinson’s Disease. 2011. Vol. 1. P 321-327.

Fleming S.M., Zhu C., Fernagut P.0. et al. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone // Exp. Neurol. 2004. Vol. 187. № 2. P 418-429.

Fleming S.M., Holden J.G., Sioshansi P.C. et al. Alterations in heart rate variability in transgenic mice overexpressing human wildtype alpha synuclein // Society of Neuroscience. Chicago: IL, 2009. № 531.9. P. K8.

Fleming S.M., Jordan M.C., Mulligan C.K. et al. Impaired baroreflex function in mice overexpressing alpha- synuclein // Front Neurol. 2013. Vol. 4. P 103.

Fornai F., Schluter O.M., Lenzi P. et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. № 9. P 3413-3418.

Forno L.S., Langston J.W., DeLanney L.E. et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP- treated monkeys // Ann. Neurol. 1986. Vol. 20. № 4. P 449-455.

Forno L., DeLanney L., Irwin I. et al. Similarities and differences between MPTP induced parkinsonism and Parkinson’s disease // Neuropathologic Considerations. Adv. Neurol. 1993. Vol. 60. P 600-608.

Forte G., Восса В., Senofonte О. et al Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson’s disease // J. Neural. Transmission. 2004. Vol. 111. P. 1031-1040.

Freed C., Revay R., Vaughan R.A. et al. Dopamine transporter immunoreactivity in rat brain // J. Comp. Neurol. 1995. Vol. 359. P. 340-349.

Freyaldenhoven T.E, Cadet J.L., Ali S.F The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in CD-1 mice are gender-dependent // Brain Res. 1996. Vol. 735. № 2. P. 232-238.

Friedman L.K., Mytilineou C. Neurochemical and toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri- dine and 1-methyl-4-phenylpyridine to rat serotonin neurons in dissociated cell cultures // J. Pharmacol. Exp. Ther. 1990. Vol. 253. № 2. P. 892-898.

FuJishiro H., Frigerio R., Burnett M. et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson’s disease // Mov. Disord. 2008. Vol. 23. P. 1085-1092.

Fukumitsu N., Suzuki M., Fukuda T. et al. Reduced 125l-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism // Nuclear Medicine and Biology. 2006. Vol. 33. P. 37-42.

Fukumitsu N, Suzuki M, Fukuda T, Kiyono Y. Multipoint analysis of reduced (125)I-meta-iodobenzylguani- dine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahy- droxypyridine-induced parkinsonism // Nucl. Med. Biol. 2009. Vol. 36. № 6. P. 623-629.

Fuller R.W., Hahn R.A., Snoddy H.D. et al. Depletion of cardiac norepinephrine in rats and mice by 1-meth- yl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) // Biochem. Pharmacol. 1984. Vol. 33. P. 2957-2960.

FullerR.W.,Hemrick-LueckeS.K. Depletion of norepinephrine in mouse heart by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) mimicked by 1-methyl-4-phenylpyridinium (MPP+) and not blocked by deprenyl // Life Sci. 1986. Vol. 39. P. 1645-1650.

Fuller R.W., Hemrick-Luecke S.K., Robertson D.W. Comparison of l-methyl-4-phenyl-l,2,3,6-tetrahydropyr- idine (MPTP) and l-methyl-4- phenylpyridine (MPP+) effects on mouse heart norepinephrine // Biochemical Pharmacology. 1988. Vol. 37. P. 3343-3347.

FullerR.W.,Hemrick-Luecke S.K., Perry K.W. Tissue conservations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice // Life Sci. 1989. Vol. 45. P. 2077-2083.

Gao H.M, Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drivesdis- ease progression // Trends Immunol. 2008. Vol. 29. № 8. P. 357-365.

Gasser P.J., OrchinikM., RaJu I., Lowry C.A. Distribution of organic cation transporter 3, a corticosterone- sensitive monoamine transporter, in the rat brain // J. Comp. Neurol. 2009. Vol. 512. № 4. P. 529-55.

Georgiev V., Kambourova T. Behavioural effects of angiotensin II in the mouse following MPTP administration // Gen. Pharmacol. 1991. Vol. 22. P. 625-630.

Gerlach M., Riederer P. Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man // J. Neural. Transm. 1996. Vol. 103. № 8-9. P. 987-1041.

Gibrat C., Saint-Pierre M., Bousquet M. et al. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions // J. Neuro- chem. 2009. Vol. 109. № 5. P. 1469-1482.

Gispert S., Del Turco D., Garrett L. et al. Transgenic mice expressing mutant A53T human alphasynuclein show neuronal dysfunction in the absence of aggregate formation // Mol. Cell. Neurosci. 2003. Vol. 24. P. 419-429.

Goldberg M.S., Fleming S.M., Palacino J.J. et al. Parkin-defi cient mice exhibit nigrostriatal defi cits but not loss of dopaminergic neurons // J. Biol. Chem. 2003. Vol. 278. P. 4328-4335.

Goldstein D.S. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities // Lancet Neurol. 2003. Vol. 2. P. 669-676.

Goldstein D.S. Dysautonomia in Parkinson disease // Compr. Physiol. 2014. Vol. P. 805-826.

GoldsteinD.S., LiS.T., Holmes C., BankiewiczK. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine primate model of Parkinson’s disease // J. Pharmacol. Exp. Ther. 2003. Vol. 306. № 3. P. 855-860.

Goldstein D.S., Imrich R., Peckham E. et al. Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation // Neurology. 2007a. Vol. 69. P. 1580-1584.

Goldstein D.S., Sharabi Y., Karp В.І. et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease // Clin. Auton. Res. 2007b. Vol. 17. P. 118-121.

Goldstein D.S., Holmes C., Kopin I.J. et al. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases // J. Clin. Investig. 2011. Vol. 121. P. 3320-3330.

Grosicka-Maciqg E., Szumilo M., Czeczot H. et al. Modulation of antioxidant defense system by the di- thiocarbamate fungicides Maneb and Zineb in Chinese hamster V79 cells and the role of N-acetyl-L- cysteine // Food Chem. Toxicol. 2013. Vol. 60. P. 130-134.

Gupta A., Dawson Kb., Dawson T.M. What causes cell death in Parkinson’s disease? // Ann. Neurol. 2008. Vol. 64. Suppl 2. P. S3-S15.

Hallett P.J., McLean J.R., Kartunen A. et al. Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits // Neurobiol. Dis. 2012. Vol. 47. P. 258-267.

Halperin I., More і.і., Korezyn M. et al. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases // J. Am. Soc. Experiment. NeuroTherapeutics. 2009. Vol. 6. P 128-140.

He Y., Lee T., Leong S.K. 6-Hydroxydopamine induced apoptosis of dopaminergic cells in the rat substantia nigra // Brain Res. 2000. Vol. 858. № 1. P. 163-166.

He Y., Appel S., Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydo- pamine injection into mouse striatum // Brain Res. 2001. Vol. 909. № 1-2. P. 187-193.

Healy D.G., FalchiM., O’Sullivan S.S. et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study // Lancet. Neurol. 2008. Vol. 7. P. 583-590.

Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4- phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity // Neurosci. Lett. 1985. Vol. 62. № 3. P. 389-394.

Herrera A.J., Castano A., Venero J.L. et al. The single intranigral injection of LPS as a new model for studying the selective effectsof inflammatory reactions on dopaminergic system // Neurobiol. Dis. 2000. Vol. 7. № 4. P. 429-447.

HerreroM.T., Hirsch E.C., Kastner A. et al. Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem // Dev. Neurosci. 1993. Vol. 15. № 1. P 37-48.

Hirsch E., GraybielA.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease // Nature. 1988. Vol. 334. №6180. P. 345-348.

Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? // Ann Neurol. 1998. Vol. 44. № 3. Suppl 1. P S115-S120.

HirschE.C., Hoglinger G.U., RousseletE. et al. Animal models of Parkinson’s disease in rodents induced by toxins: an update J. Neural. Transm. Suppl. 2003. Vol. 65. P 89-100.

Hirsch E.C., Jenner P., Przedborski S. Pathogenesis of Parkinson’s disease // Mov. Disord. 2013. Vol. 28. P. 24-30.

Hoglinger G.U., Feger J., Prigent A. et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats // J. Neurochem. 2003. Vol. 84. № 3. P. 491-502.

Hokfelt T., Ungerstedt U. Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system // Brain Res. 1973. Vol. 60. № 2. P. 269-297.

Hope A.D, Myhre R., Kachergus J. et al. Alpha-synuclein missense and multiplication mutations in autosomal dominant Parkinson’s disease // Neurosci. Lett. 2004. Vol. 367. № 1. P. 97-100.

Hou J.G., Cohen G., Mytilineou C. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system // J. Neurochem. 1997. Vol. 69. № 1. P 76-83.

Hunter R.L., Cheng B., Choi D.Y. et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice // J. Neurosci. Res. 2009. Vol. 87. № 8. P 1913-1921.

Husain M., Shukla R., Dikshit M. et al. Altered platelet monoamine oxidase-B activity in idiopathic Parkinson’s disease // Neurochem Res. 2009. Vol. 34. P. 1427-1432.

Ishizawa T.,MattilaP., DaviesP., WangD., DicksonD.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies // J. Neuropathol. Exp. Neurol. 2003. Vol. 62. № 4. P. 389-3897.

Itier J.M., IbanezP., Mena M.A. et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse // Hum. Mol. Genet. 2003. Vol. 12. P. 2277-2291.

Itzhak Y., Martin J.L., BlackM.D., Ali S.F. Effect of the dopaminergic neurotoxin MPTP on cocaine-induced locomotor sensitization // Pharmacol. Biochem. Behav. 1999. Vol. 63. № 1. P. 101-107.

Jackson-Lewis V., Jakowec M., Burke R.E. et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine // Neurodegeneration. 1995. Vol. 3. P. 257-269.

Jain S. Multi-organ autonomic dysfunction in Parkinson disease // Parkinsonism and Related Disorders. 2011. Vol. 17. P. 77-83.

Jain S., Goldstein D.S. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis // Neurobiol. Dis. 2012. Vol. 46. P. 572-580.

Jellinger KA. Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway // Mo. Chem. Neuropathol. 1991. Vol. 14. № 3. P. 153-197.

Jeon B.S., Jackson-Lewis V., Burke R.E. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death // Neurodegeneration. 1995. Vol. 4. № 2. P. 131-137.

Joers V., Emborg M. Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson’s disease // Am. J. Nuc.l Med. Mol. Imaging. 2014. Vol. 4. № 2. P. 125-159.

Johannessen J..N, Chiueh C.C., Burns R.S., Markey S.P Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects // Life Sci. 1985. Vol. 36. № 3. P. 219-224.

Jonsson G. Chemical lesioning techniques: Monoamine neurotoxins // Handbook of Chemical Neuroanatomy Vol 1: Methods in Chemical Neuroanatomy. Eds. A. Bjorklund, Т. Hokfelt. Amsterdam: Elsevier, 1983. P. 463-507.

Kalia L.V., Kalia S.K., McLean P.J. et al. a-Synuclein oligomers and clinical implications for Parkinson disease // Ann. Neurol. 2013. Vol. 73. № 2. P. 155-169.

Khaindrava LG., Kozina E.A., Kudrin V.S. et al. Experimental modeling of preclinical and clinical stages of Parkinson’s disease // Bull. Exp. Biol. Med. 2011. Vol. 5. P. 566-569.

Kim Y.S., Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis ofPar- kinson’s disease // Exp. Mol. Med. 2006. Vol. 38. № 4. P. 333-347.

Kim R.H., Amith P.D., Aleyasin H. et al. Hypersensitivity of DJ-1-defi cient mice to 1-methyl-4-ph enyl-

1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. P. 5215-5220.

KirchhoffJ.,MorkA., Brennum L.T., Sager T.N. Striatal extracellular dopamine levels and behavioural reversal in MPTP-lesioned mice // Neuroreport. 2009. Vol. 20. № 5. P. 482-486.

Kirik D., Rosenblad C., Burger C. et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system // J. Neurosci. 2002. Vol. 22. № 7. P. 2780-2791.

Klaidman L.K., Adams J.D. Jr, LeungA.C. et al. Redox cycling of MPP+: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase // Free Radic. Biol. Med. 1993. Vol. 2. P. 169-179.

Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cy- clooxygenases-1 and -2 // Mol. Cell. Neurosci. 2000. Vol. 16. № 6. P. 724-739.

Koprich J.B., Reske-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease // J. Neuroinflammation. 2008. Vol. 27. P. 5-8.

Kordower J.H., Felten S.Y., Gash D.M. Behavioral sequelae following MPTP administration in mice // MPTP: a Neurotoxin Producing a Parkinsonian Syndrome. Eds. S.P. Markey, N.Jr. Castagnoli, A.J. Trevor, I.J. Kopin. Orlando: Academic Press, 1986. P. 413-417.

Kozina E.A., Khakimova G.R., Khaindrava V.G. et al. Tyroaine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism // J. Neurol. Sci. 2014. Vol. 340. P. 198-207.

Kozlowski D.A., MilJan E.A., Bremer E.G. et al. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat // Brain Res. 2004. Vol. 1016. № 2. P. 170-181.

Kruger R., Kuhn W., Muller T. et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson‘s diseasen // Nat. Genet. 1998. Vol. 18. № 2. P. 106-108.

Kurosaki R., Muramatsu Y., Kato H. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson’s disease // Pharmacol. Biochem. Behav. 2004. Vol. 78. № 1. Р 143-153.

Kuwahara T., Kayama A., Gengyo-Ando К. et al Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans // J. Biol. Chem. 2006. Vol. 281. P. 334-340.

Langston J.W., BallardP. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease // Can. J. Neurol. Sci. 1984. Vol. 11. № 1 P. 160-165.

Langston J.W., Farna L.S. The hypothalamus in Parkinson disease // Ann. Neurol. 1978. Vol. 3. № 2. P. 129133.

Langstan J.W., Ballard P., Tetrud J.W. et al. Chronic Parkinsonism in humans due to a product of meperidine- analog synthesis // Science. 1983. Vol. 219. № 4587. P. 979-980.

Langston J.W., Irwin I., Langston E.B. et al. MPTP-induced parkinsonism in humans: A review of the syndrome and observations relating to the phenomenon of tardive toxicity // MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. Ed. S.P. Markey. Orlando (Fla.): Acad. Press, 1986. P. 9-21.

Langston J.W., Farna L.S., Tetrud J. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure // Ann. Neurol. 1999. Vol. 46. P. 598-605.

Lapointe N., St-Hilaire M., Martinali M.G. et al. Rotenone induces non-specific central nervous system and systemic toxicity // FASEB J. 2004. Vol. 18. №6. P. 717-719.

Lau Y.-S., Trabaugh K.L., Cramptan J.M. et al. Effects of probenecid on striatal dopamine depletion in acute and long-term1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice // Gen. Pharmacol. 1990. Vol. 21. P. 181-187.

Lee E.H., Lu K.T. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice // Adv. Exp. Med. Biol. 1995. Vol. 363. P. 29-46.

Lee М.К., Stirling W., Xu Y., et al. Human alpha-synuclein-harboring familial Parkinson’s disease-linked Ala-53 ^ Thr mutation mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice // Proc. Natl. Acad. Sci. USA. 2002. Vol. 99. № 13. P. 8968-8973.

Lees A.J., Hardy J., Revesz T. Parkinson’s disease // Lancet. 2009. Vol. 373. № 9680. P. 2055-2066.

LiS.T., DendiR., Holmes C. et al. Progressive loss of cardiac sympathetic innervation in Parkinson’s disease // Ann. Neurol. 2002. Vol. 52. P. 220-223.

Li W., West N., Calla E. et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. P. 2162-2167.

Li Y., Liu W., Oo T.F. et al. Mutant LRRK2 R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson’s disease // Nat. Neurosci. 2009a. Vol. 12. P. 826-828.

Li L., Whiteman M., Maare Р.К. Dexamethasone inhibits lipopolysaccharide-induced hydrogen sulphide biosynthesis in intact cells and in an animal model of endotoxic shock // J. Cell. Mol. Med. 2009b. Vol. 13. № 8B. P. 2684-2692.

LiX., Patel J.C., Wang J. et al. Enhanced striatal dopamine transmission and motor performance with LRRK- 2overexpression in mice is eliminated by familial Parkinson’s disease mutationG2019S // J. Neurosci. 2010. Vol. 30. №5. P. 1788-1797.

Lim K.L., Chew К.С., Tan J.M. et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation // J. Neurosci. 2005. Vol. 25. P. 2002-2009.

Lin J.Y., Mai L.M., Pan J.T. Effects of systemic administration of 6-hydroxydopamine, 6-hydroxydopa and 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP) on tuberoinfundibular dopaminergic neurons in the rat // Brain Res. 1993. Vol. 624. № 1-2. P. 126-130.

Lin S., Wei X., Xu Y. et al. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical- production in rat cerebellar granule neurons // Life Sci. 2003. Vol. 72. № 14. P. 1635-1641.

Linder J.C., Klemfuss H., Graves P.M. Acute ultrastructural and behavioral effects of 1-methyl-4-phenyl-

1,2,3,6- tetrahydropyridine (MPTP) in mice // Neurosci. Lett. 1987. Vol. 82. № 2. P. 221-226.

Liau H.H., Tsai M.C., Chen C.J. et al. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan // Neurology. 1997. Vol. 48. № 6. P. 1583-1588.

Liu Y., Peter D., Raghani A. et al. cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter // Cell. 1992. Vol. 4. P. 539-551.

Liu Z., Wang X., Yu Y. A Drosophila model for LRRK2-linked parkinsonism // Proc. Natl. Acad. Sci. USA. 2008. Vol. 105. P. 2693-2698.

Lookingland KJ., Moore K.E. Functinal neuroanatomy of hypothalamic dopaminergic neuroendocrine systems // Handbook of Chemical Neuroanatomoty. 2004. Vol. 20. P. 433-521.

Luthman J., Jonsson G. Effects of the parkinsonism-inducing neurotoxin MPTP and its metabolite MPP+ on sympathetic adrenergic nerves in mouse iris and atrium // Med. Biol. 1986. Vol. 64. № 2-3. P. 95-102.

Luthman J., Sundstrom E. No apparent difference in the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine (MPTP) on the sympathetic system in NMRI and C57 BL/6 mice // Toxicology Letters. 1990. Vol. 53. P. 83-92.

Luthman J,Fredriksson A., Sundstrom E. etal. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage // Behav. Brain Res. 1989. Vol. 33. № 3. P 267-277.

Mak S.K., McCormack A.L., Manning-Bog A.B. et al. Lysosomal degradation of alpha-synuclein in vivo // J. Biol. Chem. 2010. Vol. 285. № 18. P 13621-13629.

Manning-Bog A.B., McCormack A.L., Li J. et al. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein // J. Biol. Chem. 2002. Vol. 277. № 3. P. 1641-1644.

Maraganore D.M., de Andrade M., Elbaz A. et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease // JAMA. Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium. 2006. Vol. 296. № 6. P 661-670.

Marrachelli VC., Miranda FJ., Alabadi J.A. et al. Perivascular nerve fiber a-synuclein regulates contractility of mouse aorta: a link to autonomic dysfunction in Parkinson’s disease // Neurochem. Inter. 2010. Vol. 56. P 991-998.

Marsden C.D. Pigmentation in the nucleus substantiae nigrae of mammals // J. Anat. 1961. Vol. 95. P. 256261.

Martin L.J., Pan Y., Price A.C. et al. Parkinson’s disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death // J. Neurosci. 2006. Vol. 26. P. 41-50.

Martin L.J., Semenkow S., Hanaford A., Wong M. Mitochondrial permeability transition pore regulates Parkinson’s disease development in mutant a-synuclein transgenic mice // Neurobiol. Aging. 2014. Vol. 35. № 5. P 1132-1152.

Matsuoka Y., Vila M., Lincoln S. et al. Lack of nigral pathology in transgenic mice expressing human alpha- synuclein driven by the tyrosine hydroxylase promoter // Neurobiol. Diseas. 2001. Vol. 8. P. 535-539.

Mayorga AJ., Cousins G., Granutsos G., Salamono J. Animal models of parkinsonian symptoms: Effect of selective muscarinic agents on pilocarpine-induced tremulous jaw movement in rats // Abstr. Soc. Neurosci. 1996. Vol. 22. Pt. 3. P 2129.

McCormack A.L., Thiruchelvam M., Manning-Bog A.B. et al. Environmental risk factors and Parkinson’s disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat // Neurobiol. Dis. 2002. Vol. 10. № 2. P 119-127.

McCormackA.L., Di Monte D.A. Effects of L-dopa and other amino acids against paraquat-induced nigros- triatal degeneration // J. Neurochem. 2003. Vol. 85. № 1. P. 82-86.

McCoy M.K, Martinez T.N., Ruhn K.A. et al. Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tan- sey MG. Blocking soluble tumor necrosis factor signaling with dominant-negative tumornecrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease // J. Neurosci. 2006. Vol. 26. № 37. P 9365-9375.

Melamed E., Hefti F., Pettibone D.J. et al. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism // Neurology. 1981. Vol. 31. № 6. P. 651-655.

MichellA.W., LuheshiL.M., BarkerR.A. Skin and platelet a-synuclein as peripheral biomarkers of Parkinson’s disease // Neurosci. Lett. 2005. Vol. 381. P. 294-298.

Mikkelsen M., Moller A., Jensen L.H. et al. MPTP-induced parkinsonismm in mini-pigs: A behavioral, biochemical, and histological study // Neurotoxicol. Teratol. 1999. Vol. 21. P. 169-175.

MillerR.L., James-KrackeM., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson’s disease // Neurochem. Res. 2009. Vol. 34. № 1. P. 55-65.

Mitra N., Mohanakumar K.P., Ganguly D.K. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice // Brain Res. Bull. 1992. Vol. 28. P. 355-364.

Mizuno Y., Sone N., Saitoh Т. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phe- nylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain // J. Neurochem. 1987. Vol. 48. P 1787-1793.

Mogi M., Harada M., Kondo T. et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients // Neurosci. Lett. 1994. Vol. 180. № 2. P 147-150.

Mogi M, Togari A., Tanaka K. et al. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydo- pamine-lesionedstriatum in rats without influence of systemic L-DOPA on the TNF-alpha induction // Neurosci. Lett. 1999. Vol. 268. № 2. P.101-104.

Moratalla R., Quinn B. , DeLanney L.E. et al. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro- pyridine // Proc. Natl. Acad. Sci. USA. 1992. Vol. 89. № 9. P 3859-3863.

Morfini G., Pigino G., Opalach K., Serulle Y., Moreira J.E. Sugimori M., Llinas R.R. Brady S.T. 1-methyl-4- phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C // PNAS. 2007. Vol. 104. № 7. P. 2442-2447.

Morgan H.E., Baker K.M. Cardiac hypertrophy // Circulation. 1991. Vol. 83. P. 13-25.

Muralikrishnan D., Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-

1,2,3,6- tetrahydropyridine-induced neurotoxicity in mice // FASEB J. 1998. Vol. 12. P 905-912.

Muthane U., Ramsay K.A., Jiang H. et al. Differences in nigral neuron number and sensitivity to 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice // Exp. Neurol. 1994. Vol. 126. № 2. P 195-204.

Nagatsu T. Progress in monoamine oxidase (MAO) research in relation to genetic engineering // J. Neurotoxicology. 2004. Vol. 25. № 1-2. P 11-20.

Nagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines // Curr. Pharm. Des. 2005. Vol. 11. № 8. P 999-1016.

Namura I., Douillet P., Sun C.J. et al. MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons // Eur. J. Pharmacol. 1987. Vol. 136. № 1. P 31-37.

Natale G., Kastsiushenka O., Fulceri F. et al. MPTP-induced parkinsonism extends to a subclass of TH- positive neurons in the gut // Brain Res. 2010. Vol. 1355. P 195-206.

Ng с.-H., Mok S.Z.S., Koh C. et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila // J. Neurosci. 2009. Vol. 29. P 11257-11262.

Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl- 4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine // Life Sci. 1985. Vol. 36. P 2503-2508.

Nigmatullina R.R., Fedoseeva T.S., Khakimova G.R. et al. Modeling of presymptomatic and symptomatic stages of Parkinsonism in MPTP-treated mice: heart contraction adrenergic regulation and catecholamines content in blood // J. Electrocardiology. 2013. Vol. 43. P e2.

Nirenberg M.J., Vaughan R.A., Uhl G.R. et al. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons // J. Neurosci. 1996. Vol. 16. P 436-437.

ObeidR., Schadt A., Dillmann U. et al. Methylation status and neurodegenerative markers in Parkinson disease // Clinical Chemistry. 2009. Vol. 55. P 1852-1860.

O'Callaghan J.P., Sriram K., Miller D.B. Defining »neuroinflammation» // Ann. NY Acad. Sci. 2008. Vol. 1139. P 318-330.

Offen D., Beart P.M., Cheung N.S. et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity // Proc. Natl. Acad. Sci. USA. 1998. Vol. 95. № 10. P 5789-5794.

Ogawa N., Hirose Y., Ohara S. et al. A simple quantitative bradykinesia test in MPTP-treated mice // Res. Commun. Chem. Pathol. Pharmacol. 1985. Vol. 50. № 3. P. 435-441.

Orimo S., Oka T., Miura H. et al. Sympathetic cardiac denervation in Parkinson’s disease and pure autonomic failure but not in multiple system atrophy // J. Neurol. Neurosurg. Psychiatry. 2002. Vol. 73. P. 776-777.

Orimo S., Uchihara T., Nakamura A. et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease // Brain. 2008. Vol. 131. P. 642-650.

Orimo S., Uchihara T., Kanazawa T. et al. Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson’s disease // Neuropathol,. Appl. Neurobiol. 2011. Vol. 37. P 791-802.

Orr C.F., Rowe D.B., Holiday G.M. An inflammatory review of Perkinson’s disease // Progress in Neurobiology. 2002. Vol. 68. P. 325-340.

Ossowska K., Wardas J., SmialowskaM. et al. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson’s disease? // Eur. J. Neurosci. 2005. Vol. 22. № 6. P. 1294-304.

Otake К, Oiso Y., Mitsuma T. et al. Hypothalamic dysfunction in Parkinson’s disease patients // Acta. Med. Hung. 1994. Vol. 50. № 1-2. P. 3-13.

Paisan-Ruiz C., Jain, S., Evans, E.W. et al. Cloning of the gene containing mutations that cause PARK8- linked Parkinson’s disease // Neuron. 2004. Vol. 44. P. 595-600.

Palfi S., Leventhal L., Chu Y. et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration // J. Neurosci. 2002. Vol. 22. № 12. P. 4942-5494.

Paris I., Lozano J., Perez-Pastene C. et al. Molecular and neurochemical mechanisms in PD pathogenesis// Neurotox. Res. 2009. Vol. 16. № 3. P. 271-279.

Perez FA., Curtis W.R., Palmiter R.D. Parkin-defi cient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity // BMC. Neurosci. 2005. Vol. 6. P. 71.

Perez-Lloret S., Rey M.V., Fabre N. et al. Factors related to orthostatic hypotension in Parkinson’s disease // Parkinsonism and Related Disorders. 2012. Vol. 18. P. 501-505.

Perez-Otaho I., Herrero MT, Oset C. et al. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset // Brain Res. 1991. Vol. 567. №1. P. 127-132.

Pesah Y., Burgess H., Middlebrooks B. et al. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-Synuclein in Drosophila // Genesis. 2005. Vol. 41. № 4. P. 154-159.

Petroske E., Meredith G.E., Callen S. et al. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment // Neuroscience. 2001. Vol. 106. № 3. P. 589-601.

Polymeropoulos M.H., Higgins J.J., Golbe L.I. et al. Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23 // Science. 1996. Vol. 274. № 5290. P. 1197-1199.

Polymeropoulos M.H., Lavedan C., Leroy E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease // Science. 1997. Vol. 276. P. 2045-2047.

Prigione A., Piazza F., Brighina L. et al. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease // Neurosci. Lett. 2010. Vol. 477. P. 57-10.

Przedborski S., Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson’s disease // Antioxid. Redox. Signal. 2005. Vol. 7. № 5-6. P. 685-93.

Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson’s disease //Ann. NY Acad. Sci. 2003. Vol. 991. P. 189-98.

Przedborski S., Jackson-Lewis V., DJaldetti R. et al. The parkinsonian toxin MPTP: action and mechanism // Restor. Neurol. Neurosci. 2000. Vol. 16. № 2. P. 135-142.

Qin L., Wu X., Block M.L. et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration // Glia. 2007. Vol. 55. № 5. P. 4534-62.

Quintero E.M, Willis .L, Singleton R. et al. Behavioral and morphological effects of minocycline in the 6-hy- droxydopamine ratmodel of Parkinson’s disease // Brain Res. 2006. Vol. 1093. № 1. P. 198-207.

RadJa F., el Mansari M., Soghomonian J.J. et al. Changes of D1 and D2 receptors in adult rat neostriatum after neonatal dopamine denervation: quantitative data from ligand binding, in situ hybridization and iontophoresis // Neurosci. 1993. Vol. 57. № 3. P. 635-648.

Raffel D.M., Chen W., Sherman P.S. et al. Dependence of cardiac 11C-meta-hydroxyephedrine retention on norepinephrine transporter density // J. Nucl. Med. 2006. Vol. 47. P. 1490-1496.

Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria // J. Biol. Chem. 1986. Vol. 17. P. 7585-7587.

Ren J., Porter J.E., Wold L.E. et al. Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse // Neurobiology of Aging. 2004. Vol. 25. P. 131-138.

Ricaurte G.A., Langston J.W., Delanney L.E. et al. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment // Brain Res. 1986. Vol. 18. № 376. № 1. P. 117-124.

Richardson J.R., Quan Y., Sherer T.B. et al Paraquat neurotoxicity is distinct from that of MPTP and rote- none // Toxicol Sci. 2005. Vol. 88. № 1. P. 193-201.

Richfield E.K., Thiruchelvam MJ., Cory-Slechta D.A. et al. Behavioral and neurochemical effects of wild- type and mutated human alpha-synuclein in transgenic mice // Exp. Neurol. 2002. Vol. 175. P. 35-48.

Rinne J.O, Rinne J.K., Laakso K. et al. Dopamine D-1 receptors in the parkinsonian brain // Brain Res. 1985. Vol. 359.№ 1-2. P 306-310.

Robinson T.E., Whishaw I.Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats // Brain Res. 1988. Vol. 450. № 1-2. P. 209-224.

Rockenstein E., Mallory M., Hashimoto M. et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters // J. Neu- rosci. Res. 2002. Vol. 68. P. 568-578.

Rodrigyez M., Barroso-Chinea P., Abdala P. et al. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson’s disease // Exp. Neurol. 2001. Vol. 169. № 1. P 163-181.

Rojas J.C, Simola N., Kermath B.A. et al. Striatal neuroprotection with methylene blue // Neurosci. 2009. Vol. 163. № 3. P 877-889.

Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential // Brain Behav. Immun. 2003. Vol. 17. № 3. R 152-157.

Rousseaux M.W., Marcogliese P.C., Qu D. et al. Progressive dopaminergic cell loss with unilateral-to-bilat- eral progression in a genetic model of Parkinson disease // Proc. Natl. Acad. Sci. USA. 2012. Vol. 109. № 39. P 15918-159123.

Rowland N., Strieker E.M. Effects of dopamine-depleting brain lesions on experimental hyperphagia in rats // Physiol. Behav. 1982. Vol. 28. № 2. P 271-277.

Ruiz-Martinez J., Gorostidi A., Goyeneehea E. et al. Olfactory deficits and cardiac 123I-MIBG in Parkinson’s disease related to the LRRK2 R1441G and G2019S mutations // Mov. Disord. 2011. Vol. 26. P. 2026-2031.

Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress // Annu Rev Physiol. 1997. Vol. 59. P 551-571.

Saha S., GuillilyM.D., Ferree A. et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Cae- norhabditis elegans // J. Neurosci. 2009. Vol. 29. P 9210-9218.

Saint-Pierre M., Tremblay M.E., Sik A. et al. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats // J. Neurochem. 2006. Vol. 98. № 3. P 760-772.

Sakai K., Gash D.M. Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat // Brain Res. 1994. Vol. 633. № 1-2. P 144-150.

Sandmann-KeilD., BraakH. Postmortal diagnosis of Parkinson’s disease // Pathologe. 2005. Vol. 26. № 3. P. 214-212.

Samantaray S., Knaryan УН., Guyton M.K. et al. The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats // Neurosci. 2007. Vol. 146. № 2. P 741-755.

Sauer Н., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat // Neurosci. 1994. Vol. 59. № 2. P. 401-415.

Saura J, Kettler R., Da Prada M. et al. Quantitative enzyme vadio autography with 3H-Ro 41-1049 and 3H- Ro 19-6327 in vito: localization and abundance of MAO-A and MA)-B in nat CNS, ptripheral organs, and human brain // J. Neurosci. 1992. Vol. 12. P. 1977-1999.

Sehallert T., UpchurchM., WilcoxR.E. et al. Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum // Pharmacol. Biochem. Behav. 1983. Vol. 18. № 5. P 753-759.

Sehallert T., Fleming S.M., Leasure J.L. et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury // Neuropharmacology. 2000. Vol. 39. № 5. P. 777-787.

SehlossmaeherM.G., Shimura Н. Parkinson‘s disease: Assays for the ubiquitin ligase activity of neural Parkin // Meth. Mol. Bio. 2005. Vol. 301. P 351-369.

Schneider J.S. Chronic exposure to low doses of MPTP II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys // Brain Res. 1990. Vol. 534. № 1-2. P. 25-36.

Schneider J.S., DenaroFJ. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in cat and mouse brain // J. Neuropathol. Exp. Neurol. 1988. Vol. 47. № 4. P. 452-458.

Schneider J.S., Kovelowski CJ Cognitive deficits in motor asymptomatic monkeys // Brain Res. 1990. Vol. 519. № 1-2. P. 122-128.

Schneider J.S., Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey // Neurodegeneration. 1995. Vol. 4. № 3. P. 245-55.

Schneider J.S., Rothblat D.S., Distefano L. Volume transmission of dopamine over large distances may contribute to recovery from experimental parkinsonism // Brain Res. 1994. Vol. 643. P. 86-91.

Schneider J.S., Pope-Coleman A., Van Velson M. et al. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys// Mov. Disord. 1998. Vol. 13. № 4. P. 637-42.

Schuler F., Casida J.E. Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreduc- tase established by photoaffinity labeling // Biochim. Biophys. Acta. 2001. Vol. 1506. № 1. P. 79-87.

Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP // Cell. Tissue Res. 2004. Vol. 318. № 1. P. 215-224.

Schwarting R.K.W., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments // Progr. Neurobiol. 1996. Vol. 50. P. 275-331.

Schwarting R.K.W., Sedelis M., Hofele K., et al. Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson’s disease // Neurotox. Res. 1999. Vol. 1. P. 41-56.

SedelisM.,RainerK.W., SchwartingJ.P. Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease // Behav. Brain Res. 2001a. Vol. 125. P. 109-122.

SeniukNA., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP// Brain Res. 1990. Vol. 527. № 1. P. 7-20.

Shannak K, Rajput A., Rozdilsky B. et al. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson’s disease and normal subjects // Brain Res. 1994. Vol. 639. № 1. P. 33-41.

Sherer T.B., Betarbet R., Testa C.M. et al. Mechanism of toxicity in rotenone models of Parkinson’s disease // J. Neurosci. 2003. Vol. 23. № 34. P. 10756-10764.

Shimizu К, Ohtaki K., Matsubara K. et al. Carrier-mediated processes in blood--brain barrier penetration and neural uptake of paraquat // Brain Res. 2001.Vol. 906. № 1-2. P. 135-142.

Shimoji M., Zhang L., Mandir A.S. et al. Absence of inclusion body formation in the MPTP mouse model of Parkinson’s disease // Brain Res. Mol. Brain Res. 2005. Vol. 134. № 1. P. 103-108.

Singleton A.B., Farrer M., Johnson J. et al. Alpha-Synuclein locus triplication causes Parkinson’s disease // Science. 2003. Vol. 302. P. 841.

Singleton A., Gwinn-Hardy К., Sharabi Y. et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication // Brain. 2004. Vol. 127. P. 768-772.

Smeyne Rj., Jackson-Lewis V The MPTP model of Parkinson’s disease // Brain Res. Mol. Brain Res. 2005. Vol. 134. № 1. P. 57-66.

Smith P, Heath D. Paraquat // CRC Crit Rev Toxicol. 1976. Vol. 4. № 4. P. 411-445.

Smith A.D., Cohen A.D., Castro S.L. et al. Activation of the extracellular-signal regulated kinase signaling cascade by forced limb-use in a 6-hydroxydopamine Parkinson’s disease rodent model // Soc. Neurosci. 2003.

Snow Bj., Vingerhoets FJ., Langston J.W. et al. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism // J. Neurol. Neurosurg. Psychiatry. 2000. Vol. 68. № 3. P. 313-316.

Sonsalla Р.К., Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice // Eur. J. Pharmacol. 1986. Vol. 129. № 3. P. 339-345.

Spooren W.P.J.M., VassoutA., Waldmeier P., Gentsch C. Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity // Eur. J. Pharmacol. 1998. Vol. 353. P. 1-4.

Stern Y., Tetrud J.W., Martin W.R. et al. Cognitive change following MPTP exposure // Neurology. 1990. Vol. 40. № 2. P. 261-4.

Strieker E.M., ZigmondM.J. Effects on homeostasis of intraventricular injections of 6-hydroxydopamine in rats // J. Comp. Physiol. Psychol. 1974. Vol. 86. № 6. P. 973-994.

Sundstrom E., Samuelsson E.B. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropy ridine (MPTP) neurotoxicity in rodents // Pharmacol. Toxicol. 1997. Vol. 81. P. 226-231.

Sundstrom E., Luthman J., Jonsson G., Goldstein M. Determination of monoamines by use of liquid chromatography with electrochemical detection in the study of selective monoamine neurotoxins // Life Sci. 1987a. Vol. 41. № 7. P. 857-860.

Sundstrom E., Stromberg I., Tsutsumi T. et al. Olson L, Jonsson G. Studies on the effect of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice // Brain Res. 1987b. Vol. 405. № 1. P. 26-38.

Sundstrom E, Luthman J, Goldstein M, Jonsson G. Time course of MPTP-induced degeneration of the ni- grostriatal dopamine system in C57 BL/6 mice // Brain Res. Bull. 1988. Vol. 21. № 2. P. 257-263.

Takahashi R.N., Rogerio R., Zanin M. Maneb enhances MPTP neurotoxicity in mice // Res. Commun. Chem. Pathol. Pharmacol. 1989. Vol. 66. P. 167-170.

Takahashi N., Miner L.L., Sora I. et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity // Proc. Natl. Acad. Sci. USA. 1997. Vol. 18. P. 9938-9943.

Takatsu H., Nishida H., Matsuo H. et al. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG // J. Nucl. Med. 2000. Vol. 41. P. 71-77.

TanseyM.G,McCoyM.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmentaltriggers, pathways, and targets for early therapeutic intervention // Exp Neurol. 2007. Vol. 208. № 1. P. 1-25.

Tatton NA., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining // Neurosci. 1997. Vol. 77. № 4. P. 1037-48.

Tetrud J.W., Langston J.W., Redmond D.E. et al. Mptp-induced tremor in human and non-human primates // Neurology. 1986. Vol. 36. Suppl. 1. P. 308-308.

Thiruchelvam M., Brockel B.J., RichfieldE.K. et al. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? // Brain Res. 2000a. Vol. 873. № 2. P. 225-234.

Thiruchelvam M., Richfield E.K., Baggs R.B. et al. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson’s disease // J. Neurosci. 2000b. Vol. 20. № 24. P. 9207-9214.

Thiruchelvam M.J., Powers J.M., Cory-SIechta D.A., Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice // Europ. J. Neurosci. 2004. Vol. 19. P. 845-854.

Thoenen H., Tranzer J.P. On the possibility of chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine (6-OH-DA) // Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 1968. Vol. 260. № 2. P. 212-213.

Thomas B., Mandir A.S., West N. et al. Resistance to MPTP-Neurotoxicity in a-synuclein knockout mice is complemented by human a-synuclein and associated with increased P-synuclein and Akt activation // PLoS One. 2011. Vol. 6. № 1. Article ID e16706.

Tieu K. A guide to neurotoxic animal models of Parkinson’s disease // Cold Spring Harb. Perspect. Med. 2011. doi: 10.1101/cshperspect.a009316.

Tillerson J.L., Caudle W.M., Reveron M.E. et al. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine // Exp. Neurol. 2002. Vol. 178. № 1. P. 80-90.

Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds // J. Neurochem. 1993. Vol. 61. P. 1191-1206.

Tranzer J.P., Thoenen H. An electron microscopic study of selective, acute degeneration of sympathetic nerve terminals after administration of 6-hydroxydopamine // Experientia. 1968. Vol. 24. № 2. P.155-156.

Ugrumov M. Brain neurons partly expressing monoamunergic phenotype: Distribution, development, and functional signifi cance in norm and pathology // Handbook of Neurochemistry and Molecular Neurobiology. Ed. A. Lajta. Heidelberg: Springer, 2008. P. 21-53.

Ugrumov M., Khaindrava V., Kozina E. et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice // Neurosci. 2011. Vol. 181. P. 178-188.

Ukraintseva Yu.S., Shchegolevskii N.V., Korshunov V.A. et al. Modeling of the presymptomatic stage of parkinsonism in mice: Analysis of dopamine release in the striatum // Neurochem. J. 2010. Vol. 4. № 2. P. 142-147.

Umemoto S. Distributions of catecholamines in the heart of mammalian laboratory species // Bull. Yamagu- chi Med. Sch. 1984. Vol. 31. P. 71-77.

Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons // Eur. J. Pharmacol. 1968. Vol. 5. № 1. P. 107-110.

Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain // Acta. Physiol. Scand. Suppl. 1971. Vol. 367. P. 1-48.

Ungerstedt U., Arbuthnott G.W Quantitative recording of rotational behavior in rats after 6-hydroxydopa- mine lesions of the nigrostriatal dopamine system // Brain Res. 1970. Vol. 24. № 3. P. 485-493.

Vila M., Jackson-Lewis V., Vukosavic S. et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease // Proc. Natl. Acad. Sci. USA. 2001. Vol. 98. № 5. P. 2837-2842.

Viswanath V., Wu Y., Boonplueang R et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease // J. Neurosci. 2001. Vol. 21. № 24. P. 9519-9528.

Von Coelln R., Dawson V.L., Dawson TM. Parkin-associated Parkinson’s disease // Cell. Tissue. Res. 2004. Vol. 318. P. 175-184.

Wallace R.A., Boldry R., Schmittgen T. et al. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart // Life Sci. 1984. Vol. 35. P. 285-291.

Wang D., Tang B., Zhao G. et al. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons // Mol. Neurodegener. 2008. Vol. 3. P. 3.

Warenycia M.W., McKenzie G.M. Activation of striatal neurons by dexamphetamine is antagonized by degeneration of striatal dopaminergic terminals // J. Neural. Transm. 1987. Vol. 70. № 3-4. P. 217-32.

Wehrwein E.A., Parker L.M., Wright A.A. et al. Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008. Vol. 3. P. R857-863.

Weihmuller F.B., Hadjiconstantinou M., Bruno J.P., Neff N.H. Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor defi cits in MPTP-treated mice // Neurosci. Lett. 1988. Vol. 92. P. 207-212.

WeihmullerF.B., Hadjiconstantinou M., Bruno J.P. Dopamine receptors and sensorimotor behavior in MPTP- treated mice // Behav. Brain Res. 1990. Vol. 38. P. 263-273.

Westlund K.N., Krakower T.J., Kwan S.W. et al. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord // Brain Res. 1993. Vol. 612. P. 221-230.

Winkler S., Hagenah J., Lincoln S. et al. Alpha-Synuclein and Parkinson disease susceptibility // Neurology. 2007. Vol. 69. P. 1745-1750.

Wong K.K., Raffel D.M., Koeppe R.A. et al. Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET // Radiology. 2012. Vol. 265. P. 240-247.

Wu D.C, Jackson-Lewis V., Vila M. et al. Blockade of microglial activation is neuroprotective in the 1-meth- yl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease // J. Neurosci. 2002. Vol. 22. № 5. P. 1763-1771.

Yang L., Matthews R.T., Schulz J.B. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2 // J. Neurosci. 1998. Vol. 15. №18. № 20. P. 8145-52.

Yang L., Sugama S., Chirichigno J.W. et al. Minocycline enhances MPTP toxicity to dopaminergic neurons // J. Neurosci. Res. 2003. Vol. 74. № 2. P. 278-285.

Yokota T., Sugawara K., Ito K. et al. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition // Biochem. Biophys. Res. Commun. 2003. Vol. 312. P. 1342-1348.

Zarranz J.J., Alegre J., Gomez-Esteban J.C. et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia // Ann. Neurol. 2004. Vol. 55. № 2. P. 164-173.

Zhang W.., Phillips K.., Wielgus A.R.. et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson’s disease // Neurotox. Res. 2011. Vol. 19. № 1. P.63-72.

Zhu C, Vourc’h P., Fernagut P.O. et al. Variable effects of chronic subcutaneous administration of rote- none on striatal histology // J. Comp. Neurol. 2004. Vol. 478. № 4. P. 418-426.

Zigmond M.J. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism // Neurobiol. Dis. 1997. Vol. 4. №3-4. P. 247-253.

ZigmondM.J., Stricker E.M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopa- mine or lateral hypothalamic lesions // Science. 1973. Vol. 16. №182. № 4113. P. 717-720.

Zigmond M.J., Abercrombie E.D., Berger T.W. et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications // Trends Neurosci. 1990. Vol. 13. P 290-296.

Zimprich A., Biskup S., Leitner P. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology // Neuron. 2004. Vol. 44. R 601-607.

Zuch C.L., Nordstroem V.K., Briedrick L.A. et al. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion // J. Comp. Neurol. 2000. Vol. 427. № 3. P. 440-454.